Table 3:
Univariate Analysis Risk Factors for Post-COVID ALAD or Accelerated CLAD*
| ALAD or Accelerated CLAD (N= 33) | No Allograft Dysfunction (N=52) | P value | |
|---|---|---|---|
| ALAD | 26 (79%) | 0 | |
| Accelerated CLAD | 7 (21%) | 0 | |
| COVID Variant Era | |||
| Pre-delta | 10 (30%) | 13 (25%) | 0.62 |
| Delta | 5 (15%) | 13 (25%) | 0.41 |
| Omicron | 18 (55%) | 26 (50%) | 0.82 |
| Symptomatic COVID | 32 (97%) | 46 (88%) | 0.24 |
| Need for Hospitalization | 8 (24%) | 8 (15%) | 0.40 |
| COVID Vaccination | 18 (55%) | 38 (73%) | 0.10 |
| Receipt of Monoclonal Ab | 22 (66%) | 38 (73%) | 0.63 |
| Time from Transplant to COVID Diagnosis (years) | 3.49 (2.12 – 6.60) | 3.39 (1.57 – 6.40) | 0.75 |
| Age | 62 (52 – 67) | 62 (54 – 67) | 0.99 |
| Female sex | 15 (45%) | 28 (54%) | 0.51 |
| White Race | 27 (82%) | 45 (87%) | 0.55 |
| Bilateral Lung Transplant | 25 (76%) | 44 (85%) | 0.40 |
| Lung Allocation Score | 42.24 (38.36 – 52.02) | 38.71 (35.23 – 46.41) | 0.03 |
| Indication for Lung Transplant | |||
| Obstructive | 2 (6%) | 13 (25%) | 0.04 |
| Pulmonary Vascular | 0 | 3 (6%) | 0.28 |
| CF/ Bronchiectasis | 9 (27%) | 11 (21%) | 0.60 |
| Diffuse Parenchymal | 22 (66%) | 25 (48%) | 0.12 |
| Pre-existing CLAD | 11 (33%) | 8 (15%) | 0.07 |
| Diabetes | 13 (39%) | 16 (31%) | 0.48 |
| Diabetes as a risk factor for ALAD only | 12/26 (46%) | 16/59 (27%) | 0.13 |
| Last known estimated glomerular filtration rate pre-COVID (mL/min) | 43 (29 – 56) | 43 (30 – 56) | 0.85 |
| Body Mass Index | 26.7 (23.6 – 29.9) | 27.8 (24.3 – 30.1) | 0.79 |
| Antiproliferative Type | |||
| Mycophenolate | 19 (58%) | 24 (46%) | 0.38 |
| Azathioprine | 1 (3%) | 10 (19%) | 0.04 |
| Sirolimus | 2 (6%) | 3 (6%) | 1.0 |
| None | 11 (33%) | 15 (29%) | 0.81 |
*
For patients able to complete >2 spirometry assessments (>30 days apart) pre- and post-COVID